enVVeno Medical Reports Third Quarter 2022 Financial Results and Provides Corporate Update

– Ended the quarter with $42.7 million in cash and investments – Burn rate of $4.5 million for the quarter – Runway extends through the end of 2024 including release of SAVVE topline pivotal trial data and initiation of TAVVE first in human study

Thank you for visiting Tailwinds Research. We are pleased to offer free research on select small and micro cap companies. It is free to join and we hope you’ll take the time to do so.

To create an account please click on this link.

If you already have an account, please log in here.


Please enter your comment!
Please enter your name here